The Good Old Days: FDA's Jenkins Instructs Reviewers To Meet Original User Fee Review Time Standard
Executive Summary
After an almost two-year hiatus from strict adherence to the review timeframes set forth in the Prescription Drugs User Fee Act, Office of New Drugs Director John Jenkins has told the drug review staff that, once again, they should strive to meet the user fee deadlines
You may also be interested in...
'Brilliant' and 'Steady' Jenkins Retiring From US FDA's Office of New Drugs
Implementer of many drug review changes will leave in January after nearly 32 years of public service.
Orphan Designation Requests To Get Slower Reviews
FDA can't keep pace with requests, placing more pressure on sponsors to ensure submissions are complete.
Alexander Tells FDA To Create ‘Red Team’ For Regulatory Streamlining
HELP Committee Chairman Lamar Alexander wants FDA to suggest regs and other bureaucratic requirements that are hindering productivity as part of medical innovation effort.